Bromisovalum

Summary

Bromisovalum (CHEMBL1515611) is an approved small molecule (ATC N05CM03).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CM03
• Chemistry: 223.07 Da · C6H11BrN2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1515611
Name	Bromisovalum
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2447
ChEBI	CHEBI:77043
ATC	N05CM03
Molecular formula	C6H11BrN2O2
Molecular weight	223.07
InChIKey	CMCCHHWTTBEZNM-UHFFFAOYSA-N

SMILES: CC(C)C(C(=O)NC(=O)N)Br

IUPAC name: 2-bromo-N-carbamoyl-3-methylbutanamide

ChEBI definition: An N-acylurea that is urea in which one of the hydrogens is replaced by a 2-bromo-3-methybutanoyl group.

Also known as: .alpha.-bromisovalerylurea, Bromisoval, Bromisovalum, Bromovalerylurea, Bromural, Bromvalerylurea, Bromvaletone, Brovarin, Calmotin, Dagrabromyl, Dibroluur, Dormigene

Patent coverage: 429 distinct patent families (1,362 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).